SAB Biotherapeutics presents DiversitAb platform and clinical data at BIO CEO Conference

SAB Biotherapeutics, Inc.

Presentation highlighted DiversitAb platform and completed trial data showing polyclonal antibody efficacy against mutating pathogens.
No specific financial results or forward guidance were disclosed in the 8-K or presentation summary.
Audio recording and presentation slides made available on Company's IR website prior to conference.
Information furnished under Item 7.01 and not deemed filed for SEC liability purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.